Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;15(1):E58-E64.
doi: 10.5489/cuaj.6913.

Clinical dilemmas in local and regional testis cancer

Gregory J Nason  1 , Ricardo A Rendon  2 , Lori Wood  3 , Robert A Huddart  4 , Peter Albers  5 , Lawrence H Einhorn  6 , Craig R Nichols  7 , Christian Kollmannsberger  8 , Lynn Anson-Cartwright  1 , Padraig Warde  9 , Michael A S Jewett  1 , Peter Chung  9 , Philippe L Bedard  10 , Aaron R Hansen  10 , Robert J Hamilton  1
Affiliations
Review

Clinical dilemmas in local and regional testis cancer

Gregory J Nason et al. Can Urol Assoc J. 2021 Jan.

Abstract

At the Canadian Testis Cancer Workshop, the multidisciplinary management of testis cancer care was discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician's assistants, residents, fellows, nurses, patients, and patient advocacy group members.This review summarizes the discussion regarding clinical dilemmas in local and regional testis cancer. We present cases that highlight the need for a coordinated approach to individualize care. Overarching themes include the importance of a multidisciplinary approach to testis cancer, willingness to involve a high-volume experienced center, and given that the oncological outcomes are excellent, a reminder that clinical decisions need to prioritize selecting a strategy with the least treatment-related morbidity when safe.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Rendon has been an advisory board and speakers’ bureau member for, and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Wood has been an advisory board member (with no compensation) for Astellas, Pfizer, and Novartis; and has participated in clinical trials supported by Aragon, AstraZeneca, BMS, Exelixis, Merck, Pfizer, and Roche. Dr. Kollmannsberger has been an advisory board member for Astellas, BMS, Novartis, Pfizer, and Sanofi; has received honoraria from BMS, Novartis, and Pfizer; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Janssen, Merck, Novartis, Pfizer, and Sanofi. Dr. Jewett has been an advisory board member for Pfizer and Theralase Tech; has received honoraria from Olympus, Pfizer, and Theralase Tech; and holds investments in Theralase Tech. Dr. Chung has received honoraria from Sanofi and has participated in clinical trials supported by AbbVie. The remaining authors report no competing personal or financial interests related to this work.

Figures

Fig. 1
Fig. 1
Case 1: Stage 1/2A seminoma. Computed tomography demonstrating 1 cm node in left para-aortic region.
Fig. 2
Fig. 2
Case 2: Stage 2B non-seminoma. Computed tomography demonstrating being just over 1cm as described. However, once repeat 4.5 cm left para-aortic lymph node.
Fig. 3
Fig. 3
Case 3: Stage 2 B seminoma. Computed tomography demonstrating 3.7 cm node in left para-aortic region.
Fig. 4
Fig. 4
Case 4: Stage 2A seminoma. Computed tomography demonstrating
See this image and copyright information in PMC

References

    1. Canadian Cancer Statistics. A 2018 special report on cancer incidence by stage. [Accessed Sept 18, 2020]. Available at: www.cancer.ca.
    1. Znaor A, Lortet-Tieulent J, Jemal A, et al. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65:1095–106. doi: 10.1016/j.eururo.2013.11.004. - DOI - PubMed
    1. NIH. [Accessed Sept 18, 2020]. Available at: https://clinicaltrials.gov/ct2/show/NCT02537548.
    1. O’Malley ME, Chung P, Haider M, et al. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. Eur Radiol. 2010;20:1624–30. doi: 10.1007/s00330-009-1710-1. - DOI - PubMed
    1. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I non-seminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol. 2009;27:2122–8. doi: 10.1200/JCO.2008.18.8953. - DOI - PubMed

LinkOut - more resources